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Over the last decade, human neurodegenerative disorders which correlate with point
mutations in mitochondrial tRNA genes became more and more numerous. Both the num-
ber of mutations (more than 70) and the variety of phenotypes (cardiopathies, myopathies,
encephalopathies as well as diabetes, deafness or others) render the understanding of the
genotypephenotype relationships very complex. Here we first summarize the efforts under-
taken to decipher the initial impact of various mutations on the structurefunction relation-
ships of tRNAs. This includes several lines of research, namely (i) investigation of human
mitochrondrial tRNA structures, (ii) comparison of disease-related and polymorphic
mutations at a theoretical level, and (iii) experimental investigations of affected tRNAs in
the frame of mitochondrial protein synthesis. A new approach aimed at searching for long-
range effects of mitochondrial tRNA mutations on a broader global mitochondrial level
will also be presented. Initial results obtained by comparative mitochondrial proteomics
turn out to be very promising for deciphering unexpected molecular partners involved in
the pathological status of the mitochondria.
KEY WORDS: tRNA structure; aminoacylation; translation; in ûitro transcription;
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INTRODUCTION
Transfer RNAs (tRNAs) are small ribonucleic acids (62 to 95 nucleotides) present
in all organisms to ensure ribosomo-dependent protein biosynthesis (So¨ll and
RajBhandary, 1995). Main aspects of their contribution to this process are to
become charged with a specific amino acid by their cognate aminoacyl-tRNA
synthetases (aaRSs), bind to messenger RNA, and transfer the amino acid to the
nascent peptide chain at the level of the ribosome. More than 4300 sequences are
referenced in a specific database, including prokaryotic, eukaryotic-cytosolic,
-chloroplastic, and -mitochondrial (mt) molecules (Sprinzl et al., 1998). A large pro-
portion of these tRNAs, the so called ‘‘canonical tRNAs,’’ i.e., bacterial or eukary-
otic cytosolic tRNAs, have been studied in much detail and their knowledge is of
text-book value. Structural aspects (cloverleaf secondary structure, conserved sets of
primary elements, tertiary interactions, L-shaped three-dimensional structures, . . .)
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as well as functional aspects (recognition by proteic partners such as aaRS, trans-
lation initiation or elongation factors, ribosomal protein, . . .) are becoming deciph-
ered. Best known are the aminoacylation ‘‘identity sets,’’ elements allowing specific
recognition by the cognate aaRS and hindering recognition by the other synthetases
(Giege´ et al., 1993; Giege´ et al., 1998).
As opposed to canonical tRNAs, mt tRNAs form a structurally heterogeneous
family, with more or less drastic divergences from the textbook situation discussed
above, and are thus often considered as ‘‘bizarre’’ tRNAs (Dirheimer et al., 1995;
Martin, 1995; Wolstenholme et al., 1987). Although a large number of mt tRNA
sequences are presently known (about 2000) in the reference database (Sprinzl et al.,
1998), both detailed structural and functional knowledge on this class of tRNAs
remains far behind our understanding of canonical tRNAs. This is a drawback,
especially in the case of human mt tRNAs, for which more and more correlation
between point mutations in the corresponding genes and a variety of maternally
inherited neuromuscular and neurodegenerative disorders have been established over
the last 12 years (DiMauro and Andreu, 2000; DiMauro and Moraes, 1993; Larsson
and Clayton, 1995; Schon, 2000; Schon et al., 1997; Wallace, 1999). These disorders
include fatal cardiopathies, encephalopathies, myopathies, as well as deafness or
diabetes and others. Since 1990, when the first correlation between the MELAS
syndrome (mitochondrial encephalopathy with lactic acidosis and stroke-like epi-
sodes) and mutation A3243G in the tRNALeu(UUR) gene was described (Goto et al.,
1990), more than 70 different mutations can now be referred to (Kogelnik et al.,
1998). Understanding the relationship(s) between the different mt genotypes and the
different phenotypes remains of major importance. The situation is complex since a
given mutation can be associated with several types of pathologies, and, on the other
hand, a given pathology can be linked to different mutations. Moreover, different
degrees of severity in phenotypes can be observed for the same mutation. Whereas
some of these findings can be explained by mitochondria-specific features such as
mitotic segregation and threshold effect in heteroplasmy (i.e., the presence of both
wild-type and mutated versions of mt genomes in a single cell ), others remain
unexplained.
In what follows, several directions of research developed to aid our understand-
ing of the effects of point mutations in mt tRNA genes at a molecular level, will be
presented and prominent results obtained in the field will be summarized. These
include (i) structural understanding of mammalian mt tRNAs and theoretical analy-
ses of mutations observed, (ii) defects of mutated tRNAs at the level of mt trans-
lation, and (iii) long-range cellular effects of tRNA mutations by comparative mt
proteomics. Before discussing these research lines, the status of mt tRNAs in a
human cell will be recalled and the variety of mutations affecting these tRNAs in
pathologies will be presented.
HUMAN MITOCHRONDRIAL tRNAs AND THE NUCLEAR GENOME
Human mitochondria possess a small circular DNA (16659 base-pairs) which
encodes 13 protein genes (Anderson et al., 1981; Montoya et al., 1981). These pro-
teins are subunits of 4 of the 5 transmembranar respiratory chain complexes involved
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in the major energy (ATP) synthesis pathway of the cell. They consist of 7 subunits
of NADH-ubiquinone oxidoreductase (complex I), the cytochrome b apoprotein of
ubiquinone-cytochrome c oxidoreductase (complex III), 3 subunits of cytochrome c
oxidase (complex IV) and 2 subunits of ATP synthase (complex V). These mitochon-
drion-encoded subunits of the respiratory chain complexes are complemented by
about 70 subunits encoded by the nuclear genome and imported from the cytosol
(Fig. 1). For translation of the 13 mt genes, the mt genome encodes also 2 ribosomal
RNA genes and 22 tRNA genes, one tRNA specific for each of 18 amino acids,
two specific for leucine (tRNALeu(UUR), tRNALeu(CUN)) and two specific for serine
(tRNASer(AGY), tRNASer(UCN)) (the triplet indicated in brackets refers to the sequence
of the codons complementary to the tRNA anticodon, with R for purine, Y for
pyrimidine, and N for any of the 4 bases). This set of 22 is the minimal combination
necessary to read all codons present in the 13 protein genes. Thus, the importance
of each of these individual tRNAs in mt protein synthesis is well understandable.
The numerous functions of mitochondria (fatty acid degradation, Krebs cycle,
urea cycle, heme biosynthesis, ubiquinol biosynthesis, etc., reviewed by Scheffler,
1999) can only be fulfilled thanks to the import of several hundred proteins from
cytosol. These proteins include those required for the maintenance and expression
of the mt genome (replication, transcription, translation), those involved in the many
metabolic pathways, and those transmembranar proteins involved in the import
mechanisms themselves. Estimates place the number of these proteins between 600
and 2000. The mechanisms of cross-talk between the mt and nuclear genomes to
regulate the adequate number of mt proteins remain mostly unknown.
Fig. 1. Mitochondrial tRNAs in the cell. The human mt genome encodes 22 tRNAs involved in the mt
translation process, and thus in the synthesis of 13 proteins, all subunits of respiratory chain complexes
(schematized by gray arrowheads). These proteins are complemented by ∼70 nuclear-encoded subunits,
imported from the cytosol (dashed arrowheads) to allow formation of active trans-membrane respiratory
chain complexes. These complexes are involved in electron transfer and ATP synthesis. Mitochondria
contain several hundreds of additional proteins synthesized in the cytosol and imported. These include,
in particular, proteins involved in mt translation.
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In conclusion, it appears that mt tRNAs are of critical importance at different
levels. They are indispensable individual actors in the mt translation process. More-
over, since the synthesized mt respiratory chain subunits are directly linked both
physically and functionally with nuclear encoded partners, and since the correspond-
ing enzymatic complexes are located on the border line between the mt matrix and
the cellular cytosol, mt tRNAs may swell influence long-range cellular processes far
beyond mitochondria.
PATHOGENIC MUTATIONS IN MITOCHONDRIAL tRNA GENES
Mt DNA undergoes mutation at a much higher rate than nuclear genomes (e.g.,
Allen and Raven, 1996; Pesole et al., 1999). While some of the mutations are neutral
(polymorphic mutations) and contribute to the diversity of human populations (e.g.,
Ingman et al., 2000; Krings et al., 1997), many are correlated to disease (e.g.,
DiMauro and Moraes, 1993; Larsson and Clayton, 1995; Schon et al., 1997). Table
1 recalls the subset of mutations described in tRNA genes linked to disorders. So far,
20 out of 22 mt tRNA genes have been shown to be affected by mutations, and it
is likely that mutations within the two remaining genes (tRNAArg and tRNAHis) will
be described in the future. Whereas certain genes such as those for tRNALeu(UUR),
tRNALys, and tRNAIle appear as hot spots for mutations, others are less often
hit.
INVESTIGATION OF MITOCHONDRIAL tRNAs AND MITOCHONDRIAL
tRNA MUTATIONS ON A THEORETICAL LEVEL
Structural characteristics of mammalian mitochondrial tRNAs
Structure is the basis for function. Understanding the structure of mt tRNAs
will be the basis for understanding their function and will probably help us to under-
stand the effects of point mutations at a molecular level. Already while sequencing
the human mt genome in the early 80s, Anderson and colleagues noticed some
unusual features of the tRNA genes, including the absence of a complete structural
domain for one of the serine-specific tRNAs and the absence of some typically con-
served sequences for other tRNAs (Anderson et al., 1981). For example, a UUC
sequence classically converted into the TΨC sequence by post-transcriptional modi-
fication, was absent in most genes. Subsequently, the structures of three mammalian
mt tRNAs have been experimentally investigated, namely tRNAsSer(AGY) (de Bruijn
and Klug, 1983; Hayashi et al., 1997; Ueda et al., 1983), tRNAPhe (Wakita et al.,
1994), and tRNASer(UCN) (Hayashi et al., 1998; Watanabe et al., 1994), confirming
unusual folding rules for these RNAs. Complementary knowledge on structural
characteristics of each of the other human mt tRNAs came from theoretical analysis
based on the compilation of the 22 tRNA genes in 31 fully sequenced mammalian
mt genomes (Helm et al., 2000). Vertical alignments allowed us to deduce that, with
the exception of the tRNASer(AGY) group, all families of tRNAs do fold into
cloverleaf structures. However, these cloverleaves differ from the canonical ones by
large size variations, especially in the T-loops (Fig. 2). This is a striking feature since
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Table 1. Disease-related mutations in human mitochondrial tRNA genes
tRNA mutation
Amino acid
specificity Gene mutation domain position Related pathologies
Ala A5628G AC stem 31–39 CPEO
Arg
Asn A5692G AC loop 38 CPEO
C5698T AC loop 32 PEO
C5703T AC stem 27–43 CPEO, MM
Asp A7543G AC stem 29–41 MS
Cys A5814G D-stem 13–22 EM, MELAS, PEO
Gln C4332T acc. stem 3–70 EM, D
A4336G acc. stem 7–66 ADPD
instT4370 AC loop after 31 MM, CD
Glu A14709G AC loop 37 MM, EM, D
Gly T9997C acc. stem 7–66 MHCM
A10006G D-loop 18 CIPO
T10010C D-stem 12–23 EM
A10044G T-loop 59 EM
His
Ile A4269G acc. stem 7–66 FICP, EM
T4274C D-stem 13–22 CPEO
T4285C AC stem 27–43 PEO
G4298A AC stem 30–40 CPEO
G4309A T-stem 51–63 CPEO
A4317G T-loop 59 FICP
C4320T T-stem 52—62 ECM
Leu(CUN) T12297C Ac loop 33 DCM
G12301A AC loop 37 AISA
G12415A T-stem 52–62 CPEO
A12320G T-loop 57 MM
Leu(UUR) A3243G D-loop 14 MELAS, DMDF
A3243T D-loop 14 PEM, MM
G3249A D-loop 19 KS
T3250C D-loop 20 MM
A3251G D-loop 20: 01 MM
A3252G D-loop 21 MELAS
C3254G D-stem 12–23 MM
C3256T D-stem 10–25 MERRF-like, MELAS
T3258C AC stem 27–43 LA, E1
A3260G AC stem 29–41 MMC
T3264C AC loop 33 DM
T3271C AC stem 30–40 MELAS, DM
delT3272 AC stem 29–41 PEM
T3273C AC stem 28–42 O, EI
C3275A var. region 44 LHON
A3280G T-stem 49–65 MM
A3288G T-loop 57 MM
T3291C T-loop 60 MELAS
A3302G acc. stem 2–71 MM
C3303T acc. stem 1–72 MMC
Lys A8296G acc. stem 2–71 DMDF, MERRF
G8313A D-stem 12–24 MNGIE
T8316C AC stem 27–43 MELAS
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Table 1. Continued
tRNA mutation
Amino acid
specificity Gene mutation domain position Related pathologies
G8328A AC stem 31–39 EM
G8342A T-stem 53–61 PEO, MS
A8344G T-loop 55 MERRF
T8355C T-stem 50–64 PEO, SM
T8356C T-stem 49–65 MERRF
T8362G acc. stem 2–71 SM
G8363A acc. stem 1–72 MICM, D, MERRF, LS
Met T4409C acc.D-stem 8 MM
G4450A T-stem 53–61 MM
Phe G583A acc. stem 7–66 MELAS
A606G AC stem 29–41 M
T618C AC stem 29–41 MM
Pro T15965C T-stem 50–64 ADPD
G15990A AC loop 36 MM, O
Ser(AGY) C12246A T-loop 55 CIPO
C12258A acc. stem 7–66 DMDF
Ser(UCN) insG7472 var. region 46 PEM
C7497T D-stem 13–22 MM, PEM, RRF, LA
A7511G acc. stem 4–69 DEAF, SNHL
A7512G acc. stem 3–70 PEM
Thr G15915A AC stem 30–40 MM
A15923G AC loop 38 LIMM
delT15940 T-loop 60 MM
G15950A acc. stem 3–70 ADPD
Trp G5521A D-stem 10–25 MM
insT5537 AC stem after 27 MILS
G5540A AC stem 30–40 PEM, CD
G5549A AC stem 31–39 DEMCHO, D, A
Tyr A5874G D-stem 13–22 EI, LW, CD
Val G1606A acc. stem 5–68 AMDF
G1642A AC stem 27–43 MELAS
G1644T var. region 45 LS
Data have mainly been retrieved from updated database http:infinity.gen.emory.edumitomap.html. tRNA
genes are listed by amino acids specificity in alphabetical order. ‘‘Gene mutation’’ refers to the nucleotide substi-
tion and position of the mutation in the human mt genome. ‘‘tRNA mutation’’ refers to the location of the
mutation in the gene product, the acutual tRNA. Structural domains affected by the mutations refer to loops
and stems according to Fig. 2, with AC for anticodon, acc. for acceptor, var. for variable. Nucleotide numbering
is according to classical tRNA numbering (Sprinzl et al., 1998). Numbers in bold correspond to the affected
positions. Pathologies are abbreviated as follows: A-Ataxia; ADPD-Alzeimer’s Disease and Parkinsons’s
Disease; AISA-Acquired Idiopathic Sideroblastic Anemia; AMDF-Ataxia, Mental deterioration, DeaFness;
CD-Cox Deficiency; CIPO-Chronic Intestinal PseudoObstruction with myopathy; CPEO-Chronic Progressive
External Ophtalmoplegia; D-Diabete; DCM-Dilated CardioMyopathy; DEAF-Maternally inherited DEAFness
or aminoglycoside-induced DEAFness; DEMCHO-DEMentia, CHOrea; DM-Diabetes Mellitus; DMDF-Diab-
etes Mellitus, DeaFness; ECM-EncephaloCardioMyopathy; EI-Exercise Intolerance; EM-EncephaloMyopathy;
FICP-Fatal Infantile Cardiomyopathy Plus a Melas-associated cardiomyopathy; HCM-Hypertrophic Cardi-
oMyopathy; KS-Kearns-Sayre syndrome; LA-Lactic Acidose, LHON-Leber Hereditary Optic Neuropathy;
LIMM-Lethal Infantile Mitochondrial Myopathy; LS-Leigh Syndrome; LW-Limb Weakness; M-Myoglobinu-
ria; MELAS-Mitochondrial Encephalomyopathy, Lactis Acidose, Stroke-like episodes; MERRF-Myoclonic
Epilepsy and Ragged Red muscle Fibers; MHCM-Maternally inherited Hypertrophic CardioMyopathy; MICM-
Maternal; Inherited CardioMyopathy; MILS-Maternal Inherited Leigh Syndrome; MM-Mitochondrial Myo-
pathy; MMC-Maternal Myopathy and Cardiomyopathy; MNGIE-Mitochondrial NeuroGastroIntestinal Ence-
phalomyopathy; MS-Myoclonic Seizures; O-Ophtalmoplegia; PEM-Progressive EncephaloMyopathy; PEO-
Progressive External Ophtalmoplegia; SM-Skeletal Myopathy; SNHL-SensoriNeural Hearing Loss.
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T-loops are strictly conserved in size and strongly conserved in sequence in canonical
tRNAs. A second striking feature is that all mt tRNAs have a ‘‘variable region’’
which is restricted to 3 to 5 nucleotides, whereas in tRNAs of other origins, it may
have up to 23 nucleotides (Sprinzl et al., 1998).
Once secondary structural elements were aligned, it became possible to compare
primary sequences and establish consensus sequences for each of the 22 tRNA fam-
ilies. Interestingly, the degree of conservation of nucleotides within a given family
ranges from ‘‘very high conservation’’ (e.g., tRNALeu(UUR), tRNAMet, tRNAIle) to
‘‘very poor conservation’’ (e.g., tRNALys, tRNAAsp) (see examples in Fig. 2). Note-
worthy is the rarity of classically conserved nucleotides. Thus, for example, the
G18G19 doublet of the D loop is only present in 4 families out of 22, the UUC
sequence in the T-loop is rarely present, individual nucleotides such as A14, R15,
A21, and Y48 which are conserved in canonical cytosolic and bacterial tRNAs, are
also often replaced by non-conserved nucleotides. Since these nucleotides are classi-
cally involved in tertiary interactions and thus in 3D folding, it can be concluded
that folding rules for mammalian mt tRNAs, and thus for human mt tRNAs, are
probably different than for classical tRNAs, and remain to be discovered.
Establishment of the consensus secondary structures of the 22 mammalian mt
tRNAs provides a basis for experimentation and increases the fundamental knowl-
edge on structurefunction relationships of these molecules, with the goal of
deciphering the impact of mutations on these relationships.
Search for features common to the set of pathology-related mutations
Many polymorphic mutations in tRNA genes have been reported (e.g., Ingman
et al., 2000). Basic features of these mutations as well as of disease-related mutations
have been compiled and compared, with the aim of highlighting significant differ-
ences (Florentz and Sissler, 2001). Since conserved nucleotides are expected to be of
major importance in either structural or functional properties of a molecule, individ-
ual pathogenic and polymorphic mutations have been overimposed on the cognate
consensus sequences for mammalian mt tRNAs (Helm et al., 2000). As expected,
most pathogenic mutations affect highly conserved nucleotides whereas most poly-
morphic mutations affect rather non-conserved nucleotides. However, exceptions
exist, i.e., some pathogenic mutations do affect non-conserved positions and some
polymorphic mutations do affect conserved mutations, suggesting that the degree of
conservation of a nucleotide cannot be taken as a guarantee that the mutation will
be pathology-related.
Further comparison of pathogenic and polymorphic mutations concerned their
chemical type (transition, transversion), their distribution on the secondary struc-
tural domains (location in single-stranded domains), and their structural effect in
stems (type of base-pair change introduced). These simple criteria were not sufficient
to establish striking differences between both families of mutations. All mutations
are distributed rather uniformly throughout the tRNAs in both stems and loops,
they consist largely of transitions rather than transversions, and in stems, convert
Watson–Crick pairs into structurally mild CA or GU mismatches. This analysis
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showed that case by case molecular investigation remains necessary to assess the
growing family of pathogenic mutations in mt tRNAs.
SEARCH FOR EFFECTS OF MUTATIONS ON VARIOUS ASPECTS OF
MITOCHONDRIAL TRANSLATION
Considering the central role of tRNA in protein biosynthesis, obvious targets
for the investigation of mutational effects are structural and functional aspects of
the tRNA in the frame of mt translation. Global effects on translation were indeed
reported in a number of cases (e.g., Enriques et al., 1995; Hao and Moraes, 1996;
King et al., 1992; Seibel et al., 1991). Several approaches have been developed to
attempt to sort out at which precise level of tRNA biogenesis andor function the
mutations are harmful.
In ûitro analyses were based on tRNA preparation by cloning the corresponding
synthetic genes downstream from an efficient RNA polymerase promoter and in
ûitro transcription. Such an approach, giving access to any tRNA sequence in suf-
ficient amounts, had been successfully used with a large number of canonical tRNAs
and led in particular to finding aminoacylation identity elements (reviewed in Giege´
et al., 1998). In ûitro transcripts of human mt tRNAs lead to a number of surprises.
In the case of tRNALys, it became clear that the absence of post-transcriptional
modifications was deleterious to a correct folding of the tRNA (Helm et al., 1998).
Only once a single methyl group is introduced (position 1 of adenine 9), the RNA
chain folds into a cloverleaf structure (Helm et al., 1999b). In parallel to structural
weakness, transcripts also revealed non optimal in function. Thus, aminoacylation
capacity of unmodified tRNALys transcripts remains very poor (Tolkunova et al.,
2000). Further negative results on aminoacylation of in ûitro transcribed mt tRNAs
were observed for several aminoacylation systems (our unpublished results) and for
tRNAPhe (Bullard et al., 1999). In the case of tRNAIle, aminoacylation was possible
but with an efficiency 48-fold decreased in comparison to aminoacylation of the
corresponding full post-transcriptionally modified natural tRNA extracted from
placental mitochondria (Degoul et al., 1998). These examples show that the in ûitro
approach of tRNA preparation has some unexpected limitations. They also contrib-
uted strongly to the conclusion that post-transcriptional modifications are much
more important for human mt tRNAs than for canonical tRNAs. As a consequence,
it was hypothesized that pathogenic mutations could interfere with the optimal
maturation of the tRNAs, i.e., their post-transcriptional modification (see below).
Use of in ûitro transcribed tRNAs could, however, be further exploited in the
case of tRNAIle to study the effects of various mutations on the aminoacylation
capacities of the tRNA (Degoul et al., 1998; Kelley et al., 2000; Kelley et al., 2001).
As a main outcome, it was found that all mutations analyzed do affect amino-
acylation by the cognate enzyme in a more or less dramatic way by perturbing the
structure andor stability of the substrate tRNAs. Moreover, some mutated tRNAs
become inhibitors of the aminoacylation of wild-type tRNAs (Kelley et al., 2000).
This discovery highlights a new possibility of interference of mutated and wild-type
tRNAs in patient mitochondria. Indeed, in cases of mt heteroplasmy, it was pro-
posed so far that below a given threshold of mutated mt DNA, wild-type verions of
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the specific tRNA would compensate for the defective mutated tRNA. The wild-
type tRNAIle may well not be able to compensate for mutated versions, but on the
contrary, become inhibited by the defective molecules (Kelley et al., 2000).
Analysis of natural wild-type and mutated tRNAs extracted from cybrid cell-
lines confirmed to some extent the possibility that mutations linked to pathologies
can interfere with post-transcriptional modifications. Experiments were performed
to explore tRNALys mutated at position 8344 (related to the MERRF syndrome, see
Table 1) and tRNALeu(UUR) mutated at position 3243 (related to the MELAS syn-
drome). A detailed quantitative comparison of each post-transcriptional modifi-
cation present in wild-type and mutated tRNALys (6 modifications) and in wild-type
and mutated tRNALeu(UUR) (9 modifications) extracted from osteosarcoma cell lines,
revealed that none of the modifications is affected by the mutation in tRNALys
and that one specific modification, m2G10, is reduced by 50% in the mutated
tRNALeu(UUR) (Helm et al., 1999a). The level of post-transcriptional modifications at
the anticodon wobble position (position 34), a position known as important for
codon reading, was difficult to investigate but was evaluated as poorly modified in
both wild-type and mutated tRNALys and tRNALeu(UUR) (Helm et al., 1999a). A
distinct technique of post-transcriptional modification analysis, applied to tRNAs
extracted from HeLa cells derived cybrids, brought information only on these these
positions (Yasukawa et al., 2000b; Yasukawa et al., 2000c). It was found that
whereas wild-type tRNALys and tRNALeu(UUR) are fully modified at position 34,
mutated versions of the tRNAs are not at all. It has further been demonstrated that
the mutated tRNAs are unable to bind to ribosomes (Yasukawa et al., 2001).
Although the two approaches applied to investigate the post-transcriptional modifi-
cations in mutation-carrying tRNAs lead to variable results, they both argue in
favor of a correlation between mutations and post-transcriptional modification
levels.
Further analyses on natural human mt tRNAs (extracted from cybrids or from
biopsies) confirm and extend the impact of mutations to tRNA structure and biogen-
esis as well as to function. Indeed, abnormal transcription, e.g., (Bindoff et al., 1993;
King et al., 1992; Koga et al., 1995; Schon et al., 1992), incomplete maturation
(Fierl et al., 1997; Levinger et al., 2001; Rossmanith and Karwan, 1998), incomplete
post-transcriptional modification (see above), and lower stability (Chomyn et al.,
2000; Enriquez et al., 1995; Hao and Moraes, 1997; Yasukawa et al., 2000a) were
observed for mutated tRNAs as compared to corresponding wild-type reference.
The aminoacylation capacity of mutated tRNAs was found to be less efficient and
or less specific (Chomyn et al., 2000; Enriquez et al., 1995), or at opposite not
affected (Bo¨rner et al., 2000; Yasukawa et al., 2001). In some cases, frameshifting
(Masucci et al., 1995; Masucci and Schon, 1996) or slower polysome formation
(Chomyn et al., 2000) has been observed.
In summary, our present knowledge on the molecular impact of point mutations
on human mt tRNA structure and function in translation is still puzzling. Whereas
so far only a subset of mutations has been experimentally analyzed, effects reported
are rather variable. The variability concerns the type of effect as well as the quanti-
tative aspects which are likely linked to the nuclear backgrounds of the investigated
cells (different cybrid cell lines, biopsies). However, despite the apparently conflicting
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results, many efforts are being made to try to solve the controversies and understand
the diversity in molecular effects of mt tRNA mutations (e.g., Jacobs and Holt,
2000). While, so far, all molecular investigations have focussed on possible effects
of mutations on conventional aspects of tRNAs in the frame of mt translation, it is
possible that ‘‘the primary effect of the mutation on tRNA function may yet prove
to be something that nobody has yet thought of.’’ Such as hypothesis, proposed by
several authors during the last decade and recalled provocatively recently (Jacobs
and Holt, 2000), is indeed a challenging complementary possibility.
In what follows, a new approach of comparative mt proteomics will be
described. Instead of searching for unexplored primary effects of mutations, this
technique will investigate long-range secondary effects at the level of mitochondria
as a global entity, and on the mtnuclear genomes relationship. Such a global
approach should allow to highlight alternative pathways to mt translation, which
may be affected by the tRNA mutations. First promising results are presented.
SEARCH FOR LONG-RANGE EFFECTS OF tRNA MUTATIONS BY A
COMPARATIVE PROTEOMIC APPROACH
Biochemical analyses of disease-related mitochondria generally highlight
decreased oxygen consumption, decreased activities of respiratory chain complexes,
and as a consequence, decreased rates of ATIP synthesis. Additional biological
changes have been observed including lactic acidosis (Wallace, 1999), increased oxi-
dative stress (Wallace, 1999), altered membrane potential (Antonicka et al., 1999)
and apoptotic events (Asoh et al., 1996; Mirabella et al., 2000). Thus, additional
molecular consequences of the primary effects of mutations occur in mitochondria
as well as at the more global cellular level. These considerations suggest that global
approaches, in addition to direct investigations, are required to understand the mol-
ecular effects of individual mutations in mt tRNAs and the relationship of these
effects with the phenotypic expression of the disease. To test such possibilities, we
have initiated a comparative proteomic approach on mitochondria extracted from
couples of cybrid cell-lines representative of two point mutations, namely the
MERRF related mutation 8344 and the MELAS related mutation 3243 (Rabilloud
et al., 2002).
Proteomics consist of a high resolution separation of thousands of proteins at
once, by 2D separation on polyacrylamide gels, and amino acid analysis (e.g., Wil-
kins et al., 1997). In a first dimension, proteins are separated according to their
isoelectric point (pI) and in second dimension, according to their mass. This tech-
nique pioneered 20 years ago by O’Farrell (O’Farrell, 1995), gained much focus
recently thanks to technological improvements combined with sensitive mass-spec-
trometric measurements allowing the assignment of individual proteins. To search
for long-range effects of point mutations in mt tRNAs on the total mt protein con-
tent, we have explored the feasibility of comparative proteomics. This is based on a
precise quantitative comparison of 2D maps obtained from mitochondria prepared
from related cybrid cell-lines, cells with a same nuclear background and different
only at the level of the single point mutation in the gene of one given mt tRNA.
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The reference cell-line carries the wild-type tRNA gene, the other cell-line carries
the mutated gene.
Long-range effects of mitochondrial tRNA mutations on nuclear-encoded proteins
2D separation of the human mt proteins has been pioneered by Rabilloud and
colleagues (Rabilloud et al., 1998), with much emphasis on solubilizing the numerous
membrane proteins. While this still remains a limitation, it is however possible to
observe about 1000 well-separated protein spots on a single silver-stained gel. When
applied to mitochondria extracted from couples of related cybrid representative of
mutation A8344G linked to the MERRF syndrome, and of mutation A3243G
related to the MELAS syndrome, about 1000 spots are also observed (Fig. 3). While
most spots are of similar intensity, numerous differences between the patterns of
wild-type and mutation-carrying mitochondria can be observed by simple visual
inspection, demonstrating that both down- and up-regulations of several proteins
take place in the affected mitochondria. As illustrated in Fig. 3 for a subset of
proteins, two spots, X and Y, undergo drastic down-regulation in mitochondria
related both to the MERRF and to the MELAS syndrome. Assignment of the pro-
teins present in these spots by a combination of mass spectrometric techniques
(MALDI-TOF, MS-MS) and Edman degradation revealed two nuclear-encoded
subunits of a respiratory chain complex, cytochrome c oxidase (COX subunits Vb
and VIa). COX consists of 13 subunits, 3 mitochondrially encoded and 10 of nuclear
origin (Scheffler, 1999). It is already well established that both MERRF mutation
A8344G and MELAS mutation A3243G interfere with the synthesis of the mt sub-
units, COX-I, COX-II, and COX-III (e.g., Enriquez et al., 1995; Chomyn et al.,
2000). The comparative proteomic approach reveals that at least two additional
subunits are affected, although they are nuclear-encoded. This was an initial step
confirming that there are long-range consequences of a mutation in a mt tRNA
gene. Interestingly, the same two proteins are affected for the two tRNA mutations
considered, highlighting the possibility of common molecular mechanisms in the
phenotypic expression of both MELAS and MERRF syndromes.
The next step in the proteomic approach will be complete computer assisted
quantitative comparison of 2D patterns, and thus detection of those individual pro-
teins which undergo the most important down- or up-regulation. It will then be of
highest interest to assign these proteins by mass spectrometry and verify if these
proteins further belong to nuclear-encoded respiratory chain subunits of if they
correspond to enzymes of metabolic pathways, to proteins involved in mt translation
or to other proteins. Whatever the surprise will be, knowledge of these proteins will
enrich our global view of the major events taking place in the mutation-carrying
mitochondria. These events may reveal further negative consequences of the
mutations andor compensatory events established by the cell to somehow overcome
the primary effects of the mutation.
Long-range effects between mt and nuclear genomes have already been demon-
strated, as for example, after complete blocking of mt genome expression (ρ° cells),
or after complete inhibition of mt translation by antibiotics (Nijtmans et al., 1995).
However, the approaches used so far to detect affected proteins (specific antibodies)
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Fig. 2. Structural features of mammalian mitochondrial tRNAs. (A) Typical secondary structure of mam-
malian mt tRNAs (right) as compared to ‘‘classical’’ tRNA (left). Especially striking are the size varia-
bility of D- and T-loops, the anticodon stem, the connector between the acceptor and the D-stems, and
the rarity of conserved nucleotides. Even residue U33 in the anticodon loop (marked by an ∗) is not
conserved in all families, the noticeable exception being the methionine-specific tRNAs with C33. Num-
bering is according to (Sprinzl et al., 1998), R stands for purine, Y for pyrimidine, T for thymine, and Ψ
for pseudouridine. The broken line recalls that in mammlian mt tRNA
Ser(AGY)
, the complete D-arm is
missing. (B) Primary sequence conservation in mammalian mt tRNAs with the examples of tRNA
Ile
(strongly conserved, left) and tRNA
Lys
(partially conserved, right). The degree of conservation of each
nucleotide within 31 mammalian sequences, are indicated by the background color (100% conservation,
dark; conservation over 90%, light gray; conservation to more than 50% but less than 90%, white).
Squares indicate conservation of purines of pyrimidines, and circles indication non-conservation. Arrow-
heads in tRNA
Lys
indicate the presence of additional nucleotides in some of the analyzed sequences. Data
are according to Helm et al., 2000.
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Fig. 3. Proteomics as a potential tool for the exploration of mt disorders. The approach includes two-
dimensional separation of human mt proteins by isoelectrofocusing and polyacrylamide gel electrophor-
esis. A typical silver-stained gel obtained on mitochondria extracted from a wild-type cybrid cell line is
shown. Quantitative comparison between the 2D patterns obtained for wild-type and mutation-carrying
mitochondria allows the determination of effects on proteins in the disease-representative mitochondria.
Histograms in the right part of the figure illustrate this step by comparison of 4 spots in experiments
performed to investigate the MERRF mutation A8344G in tRNA
Lys
(upper part) and the MELAS
mutation A3243G in tRNA
Leu(UUR)
(lower histogram). Quantification is done by PD-Quest software (BIO-
RAD). In both couples, proteins in spots 1 and 2 are rather unaffected whereas proteins in spots X and
Y are very strongly decreased in the disease-carrying mitochondria. Assignment of these two spots by
mass spectrometric techniques (MALDI-TOF) revealed nuclear encoded subunits of cytochrome c oxi-
dase, a respiratory chain complex (bottom). The approach is based on trypsin digestion of the proteins,
and mass measurements of the different peptides (those peaks labeled with a star correspond to internal
mass controls). The combination of masses is submitted to database searches and the best fits with protein
sequences are reported.
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necessarily limited the number of proteins analyzed. Thanks to the sensitivity of
mass spectrometric techniques, proteomics allows any protein seen on the gel to be
assigned as long as its sequence is present in databases. Additionally, use of cybrid
cell lines allows one to circumscribe the effects of a single point mutation in a given
mt tRNA gene, rather than to determine effects of complete translation inhibition.
Comparative proteomic analysis of mt proteins from various cybrid cell lines, rep-
resentative of as many tRNA mutations as possible, or from biopsies, will certainly
highlight sensitive distinctions in the patterns of affected proteins and thus contrib-
ute to our understanding on the relationships between genotypes and phenotypes.
Proteomics has already proven to be very efficient in the understanding of diseases
or in diagnosis (e.g., Celis et al., 2000). Further applications include mt disorders
linked either to mt genome mutations in rRNA or protein genes, or to nuclear
mutations (Schon, 2000). A recent investigation on mt proteins from neuroblastoma
cell-lines representative of Alzheimer’s disease illustrates these possibilities (Scheffler
et al., 2001).
CONCLUSION
More than 115 different disease-related mutations have been found throughout
the mt genome (Kogelnik et al., 1998) with 38% occurring in protein genes (respira-
tory chain subunits), and 62% in mt protein synthesis related genes (4% in ribosomal
and 58% in tRNA genes). Since each tRNAs and rRNAs is involved in a common
pathway, it could have been expected that all mutations taking place in the corre-
sponding genes would lead to (i) a same molecular effect, namely a decreased rate of
synthesis of the 13 mt-encoded proteins, (ii) a same metabolic consequence, namely
decrease in ATP synthesis, and (iii) same phenotypic consequences. This is, however,
a too simplisitc view, biased at many steps, so that today no common simple mech-
anistic process can explain the effects of the mutations. As briefly summarized in
this review, the various combinations of model systems and mutations analyzed so
far recall, indeed, that the translation process itself can be affected by tRNA
mutations in many different ways, both qualitatively and quantitatively. These vari-
ations may well be dependent on the molecular environment of the affected tRNA
within the mitochondria, environment which is likely different according to the
nuclear background. Long-range effects of the mutations, as observed in initial pro-
teomic studies, contribute to the expression of the disease as well. Further investi-
gations both in the frame of mt protein biosynthesis and in the larger frame of
integrated biological aspects of mitochondria in the cell, are clearly needed to better
understand the genotypephenotype relationships of mt tRNA disorders.
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